➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Johnson and Johnson
AstraZeneca
Baxter
Mallinckrodt

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,486,456


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,486,456 protect, and when does it expire?

Patent 8,486,456 protects ONMEL and is included in one NDA.

This patent has eight patent family members in five countries.

Summary for Patent: 8,486,456
Title:Itraconazole compositions with improved bioavailability
Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>.DELTA.H.sub.tr (1) (wherein .DELTA.H.sub.tr represents the endotherm (J/g) accompanying a transition at about 240.degree. C). The solid dispersion product shows an improved bioavailability.
Inventor(s): Berndl; Gunther (Herheim am Berg, DE), Degenhardt; Matthias (Limburgerhof, DE), Maegerlein; Markus (Mannheim, DE), Dispersyn; Gerrit (Pennington, NJ)
Assignee: Abbott GmbH & Co., KG (Wiesbaden, DE)
Application Number:11/997,256
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,486,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,486,456

PCT Information
PCT FiledAugust 08, 2006PCT Application Number:PCT/EP2006/007839
PCT Publication Date:February 15, 2007PCT Publication Number: WO2007/017248

International Family Members for US Patent 8,486,456

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2618255 ⤷  Free Forever Trial
European Patent Office 1912625 ⤷  Free Forever Trial
Spain 2571032 ⤷  Free Forever Trial
Japan 2009504589 ⤷  Free Forever Trial
Japan 2014062110 ⤷  Free Forever Trial
Japan 5538718 ⤷  Free Forever Trial
Japan 5763735 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Medtronic
Moodys
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.